Nuzefatide Pevedotin for Pancreatic Cancer

This trial tests a new drug, nuzefatide pevedotin (BT5528), to evaluate its effectiveness for individuals with a type of pancreatic cancer that has progressed after one treatment. The drug targets a specific protein in the cancer cells. The study examines the drug's efficacy, potential side effects, and how the body processes it. Suitable participants have pancreatic ductal adenocarcinoma that has worsened after one treatment and can provide a tumor sample for testing. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group, offering a chance to contribute to significant advancements in cancer therapy.

The trial requires that you stop chemotherapy or radiotherapy at least 14 days before starting the study treatment. If you are on experimental treatments, you need to stop them 28 days or 5 half-lives before the first dose of the study drug, whichever is longer.

Studies have shown that nuzefatide pevedotin, the drug tested in this trial, has generally been well-tolerated by patients. Research involving over 150 people suggests that the treatment is likely safe. Most patients experienced only minor side effects, and researchers deemed the treatment safe enough to continue testing.

Nuzefatide Pevedotin (BT5528) is unique because it offers a novel approach to treating pancreatic cancer by targeting specific proteins on cancer cells. Unlike standard treatments like chemotherapy, which affects both healthy and cancerous cells, BT5528 is designed to precisely attack cancer cells with minimal impact on normal tissue. Researchers are excited about this treatment because it has the potential to reduce side effects and improve patient outcomes by delivering a more targeted and effective therapy.

Research has shown that nuzefatide pevedotin targets a protein called EphA2, often found in pancreatic cancer cells. In early studies, nuzefatide slowed tumor growth in models of pancreatic cancer made from patient samples. The data also indicate that nuzefatide was well-tolerated, causing no severe side effects. Encouragingly, it showed early signs of effectiveness against cancer when combined with another drug, nivolumab. These findings suggest that nuzefatide could be an effective treatment for pancreatic cancer. Participants in this trial will receive nuzefatide pevedotin as a monotherapy to further evaluate its effectiveness and safety.¹⁴⁵⁶⁷